Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Analysts

Celcuity Inc. (NASDAQ:CELC) has received an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $29.17.

Several equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a report on Friday, November 15th. Stifel Nicolaus lifted their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th.

Celcuity Stock Up 1.0 %

NASDAQ:CELC opened at $12.53 on Friday. Celcuity has a 1-year low of $11.51 and a 1-year high of $22.19. The company has a market capitalization of $465.24 million, a PE ratio of -4.80 and a beta of 0.74. The firm’s 50-day moving average price is $14.03 and its 200-day moving average price is $15.38. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Institutional Investors Weigh In On Celcuity

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in Celcuity during the 3rd quarter valued at $33,000. Prospera Private Wealth LLC bought a new stake in shares of Celcuity in the third quarter worth $35,000. Values First Advisors Inc. purchased a new stake in Celcuity during the third quarter valued at $86,000. Quest Partners LLC increased its position in Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after acquiring an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Celcuity in the third quarter valued at about $119,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.